Recursion Pharmaceuticals
clinical patient population easily identifiable autosomal dominant tumor predisposition syndrome caused by a mutation in the gene classic mutation hundreds to thousands of polyps in colon and upper tract manifestations desmoid tumors likelihood of developing cancer before age if untreated disease overview familial adenomatous polyposis | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
106 of 143
Related slides by other companies
argenx SE
Investor Presentation
March 2023
musk agonist with broad potential in neuromuscular disease | argenx SE
argenx SE
Investor Presentation
June 2023
musk agonist with broad potential in neuromuscular disease | argenx SE
argenx SE
Investor Presentation
November 2023
musk agonist with broad potential in neuromuscular disease clinical | argenx SE
argenx SE
Investor Presentation
February 2023
musk agonist with broad potential in neuromuscular disease | argenx SE
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io